Gerresheimer Faces Critical Juncture Amid Restructuring and Scrutiny

German pharma packager Gerresheimer navigates BaFin audit, covenant breach, and sale of profitable US unit Centor as investors take opposing views.

The German pharmaceutical packaging supplier Gerresheimer finds itself at a pivotal moment. A series of interconnected challenges—from regulatory probes to a major asset sale—are testing the company's resilience as it navigates a complex restructuring phase.

Regulatory Scrutiny Intensifies and Accounting Issues Surface

A significant overhang for the company is an expanding examination by the German financial regulator, BaFin. The authority initiated a special audit in September 2025 and broadened its scope in early March 2026. This action stems from an independent law firm's discovery that revenues from specific "bill-and-hold" agreements were systematically recognized prematurely, constituting a clear breach of International Financial Reporting Standards (IFRS).

The delayed publication of audited financial statements has triggered a breach of the company's existing financing covenants. Gerresheimer is currently engaged in talks with its lenders to secure deadline extensions. Should these negotiations fail, creditors could exercise their contractual rights, adding financial pressure.

Auditing firms KPMG and Grant Thornton are now jointly reviewing the company's financial statements for 2024 and 2025.

Strategic Divestment of a Crown Jewel

Central to Gerresheimer's restructuring is the planned sale of its US subsidiary, Centor Inc., a leading provider of packaging systems for prescription drugs. The company has mandated Morgan Stanley to advise on the transaction, which it aims to finalize within the current year. Management has expressed confidence, citing strong buyer interest.

This move, however, presents a double-edged sword. While a sale would generate urgently needed capital, it also risks further diluting the group's overall profitability. Centor, carried on the books at 292 million euros as of late 2024, is considered one of the most profitable segments within the portfolio.

Asset Impairments and Operational Shifts

Further straining the balance sheet, Gerresheimer anticipates non-cash impairment charges totaling between 220 and 240 million euros. These write-downs primarily relate to technology projects at Sensile Medical AG and the Moulded-Glass production site in Chicago Heights.

The Chicago Heights facility is slated for closure by the end of the 2026 fiscal year, with its business operations being transferred to plants in Italy and India.

Investor Sentiment Remains Divided

The shareholder base reflects a stark contrast in perspectives. The German shareholder association DSW has commissioned a legal opinion on the liability of former executives and is evaluating potential damage claims against ex-CEO Dietmar Siemssen and ex-CFO Bernd Metzner.

Conversely, some investors appear to see value at current depressed price levels. The CastleKnight Master Fund and Deka Investment have recently disclosed new stakes in the company, signaling a view that the present valuation may offer an entry point.

Market speculation has also been fueled by unconfirmed reports that packaging rival Silgan could be preparing a bid exceeding 40 euros per share—a premium of roughly 80% to recent trading prices. No formal offer has been presented to date.

Outlook Hinges on Key Deliverables

For the 2026 fiscal year, Gerresheimer has provided guidance forecasting revenue of 2.3 to 2.4 billion euros and an adjusted EBITDA margin of 18% to 19%. The credibility of this outlook, however, remains in question pending several critical milestones.

The market awaits the certified annual financial report, due in June 2026. This document, alongside the outcomes of the ongoing lender negotiations and the BaFin proceedings, will serve as decisive markers for Gerresheimer's future trajectory. The company's exclusion from the SDAX index has already been executed, underscoring its current period of significant transition.